PR Newswire · Feb 2026
Announced a collaboration to build a Bay Area GMP manufacturing facility combining cyanobacteria-based oral biologics with Persist AI's robotic formulation and process-optimization platform.
Developing long-lasting drug formulations 50% faster
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Persist AI is a West Sacramento–based pharmaceutical manufacturing company building an AI- and robotics-driven platform to accelerate drug formulation development, with a particular focus on long-acting injectables and other hard-to-formulate drug products. Its offering combines cloud-accessible AI, robotic execution, and formulation expertise to help pharma teams move faster from molecule to product.
Primary product
Persist AI Cloud Lab / AI-driven robotic formulation platform
Founded
2022
Headquarters
890 Embarcadero Dr, West Sacramento, CA 95605, United States
Team size
20-30
Industry
Pharmaceutical Manufacturing
Sub-industry
AI-driven drug formulation, robotics-enabled pharmaceutical R&D, and preclinical formulation CRO/CDMO services
Offices
890 Embarcadero Dr, West Sacramento, CA 95605 (HQ)
890 Embarcadero Drive, CoLaborator Space, West Sacramento, California, United States
1100 Main Street, Woodland, 95695, United States
1001 Riverside Pkwy, West Sacramento, CA 95605
Business model
Fee-for-service formulation development
Robotic cloud lab services
AI platform / software deployment in client cloud
Funding
Stage
Series A
Total raised
$16.6M
Latest round
Series A · May 2025
Latest amount
$12M
May 2025 · Spero Ventures
Aug 2023 · 2048 Ventures
Apr 2023 · Y Combinator
Mar 2023
People & investors
Leadership
Co-Founder & CEO
Co-Founder & COO
Vice President of Business Development
Amjad Basha Mohammad
Head of Advanced Manufacturing
Brooke Kennedy
HR Director
Work & culture
The company presents itself as a small, cross-disciplinary team of scientists and engineers with a fast-moving, mission-driven culture centered on collaboration, automation, and accelerating patient access to better therapies.
Compensation
No public salary bands were found. A third-party LinkedIn-style employer snapshot shows a strong compensation sentiment signal (5.0/5.0 compensation subscore from 1 review), but that is not an explicit pay range.
Product & market
Pricing
Custom-quote, B2B service model with tiered offerings: Persist AI Suite, Cloud Lab, and Full Service formulation development.
Differentiators
- —AI-first formulation platform
- —Custom robotics designed for organic solvents and complex materials
- —Microfluidics for miniaturized but scalable formulation development
- —Proprietary structured datasets linked to manufacturing parameters
- —Cloud-accessible experiment design and execution
- —Claims of materially faster formulation cycles than traditional methods
- —cGMP-compatible manufacturing buildout
Technology
AI/ML models
robotics
automation
microfluidics
computational chemistry
molecular dynamics
thermodynamic modeling
Bayesian optimization
Flask
MasterControl
HubSpot
Salesforce
Mailchimp
LinkedIn Sales Navigator
Customers
Pharmaceutical companies
Drug manufacturers
Contract research organizations (CROs)
Teams developing long-acting injectables
Teams developing oral peptide/protein therapeutics
Competitors
Lonza
Catalent
Micromacinazione / Microsize
other formulation-development CROs and CDMOs
other AI-assisted formulation platforms
Scale & contact
Estimated revenue
About $3.8M ARR (2024 estimate); other third-party profiles place it in the $1M-$10M range.
Estimated monthly visits
3.3K
Traffic estimate as of Jul 2026
Latest news
Persist AI · Jun 2025
Official leadership expansion announcement adding Amjad Basha Mohammad as Head of Advanced Manufacturing and Ramesh Rachapudi as VP of Business Development.
PR Newswire · May 2025
Announced the Cloud Lab platform and a $12M Series A led by Spero Ventures with participation from strategic and venture investors.
PR Newswire · Aug 2024
Announced a collaboration to co-develop an AI-driven manufacturing process for long-acting injectable drugs with Nivagen Pharmaceuticals.
PR Newswire · Aug 2023
Announced a $4M seed financing round led by 2048 Ventures with participation from Innospark Ventures, Fellows Fund, Y Combinator, Pioneer Fund, and others.
Jobs and careers at Persist AI
0 jobs at Persist AI
No open positions
Check back later for new openings